Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exicure, Inc.

7.93
+0.21502.79%
Post-market: 8.000.0750+0.95%19:42 EDT
Volume:95.13K
Turnover:726.78K
Market Cap:50.07M
PE:-4.26
High:8.09
Open:7.71
Low:7.30
Close:7.71
Loading ...

Exicure Media Files Secondary Offering for Investors

MT Newswires Live
·
15 Jul

BRIEF-Exicure Files For Prospectus Offering 5.2 Mln Common Stock Offered By Selling Stockholders

Reuters
·
15 Jul

Exicure: Files for Prospectus Offering 5.2 Mln Common Stock Offered by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
14 Jul

Exicure Inc trading resumes

TIPRANKS
·
03 Jul

Is Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?

TIPRANKS
·
30 Jun

Exicure Shares Up After Swing to Profit in 1Q

Dow Jones
·
28 Jun

Exicure Q1 EPS $0.49 Up From $(0.48) YoY

Benzinga
·
28 Jun

Exicure Inc. Reports Q1 2025 Net Income of $3M, Driven by Lease Liability Reversal, Despite Increased Operating Expenses

Reuters
·
28 Jun

Exicure, Inc. Reports First Quarter 2025 Financial Results

THOMSON REUTERS
·
28 Jun

Exicure Q1 Net Income Before Tax USD 3.01 Million

THOMSON REUTERS
·
28 Jun

Exicure Inc. Announces Executive Management Compensation Adjustments and Severance Packages

Reuters
·
11 Jun

Exicure Inc. Receives Nasdaq Notice for Delayed Q1 Financial Report Filing

Reuters
·
29 May

Exicure Inc. Announces Delay in Q1 2025 Financial Reporting Due to Acquisition Accounting

Reuters
·
16 May

Exicure Inc. Announces Convertible Bond Redemption with KC Creation Co., Ltd

Reuters
·
07 May

Exicure completes patient enrollment in GPC-100 trial

TIPRANKS
·
05 May

Exicure Completes Patient Enrollment in Phase 2 Study of Gpc-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

THOMSON REUTERS
·
05 May

Exicure Inc: Topline Results Expected H2 2025

THOMSON REUTERS
·
05 May

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Business Wire
·
05 May

Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma

MT Newswires Live
·
15 Apr

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Business Wire
·
15 Apr